WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage ...

CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Although recent advancements in CFTR modulator therapies have improved outcomes for many people ...

The company, focused on advancing treatments for cystic fibrosis (CF) by normalizing CFTR protein function, began trading on the Nasdaq under the ticker "SION" on February 7, 2025. The IPO's ...

The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF). Companies valued at $10 billion or more are generally classified as ...